Tahir Amin: Drug Prices in Advertising

Tahir Amin, DipLP, co-founder and director of intellectual property of Initiative for Medicines, Access, and Knowledge, discusses whether including drugs' list prices in consumer advertising will help drive down prices for patients.
December 07, 2018


Would disclosing drugs' list prices in ads help drive down prices for patients?

To be honest, I don’t think disclosing list prices is really going to have the difference that we need to see in the current marketplace, in the current crisis that we’re facing regarding drug pricing.

I think it’s useful to have the list pricing there, but will that really change essentially where the abuse is really happening? We believe it has to lie in changing the patent system, in changing how we hand out 20-year monopoly periods to companies. Until you do that, you really aren’t going to see marked changes, and companies will find other ways to strategically cover up the list pricing in other ways.

I don’t think that’s a measure that really helps. I think that’s really a deflection, if anything, [rather than] going to the source of the problem.


Health economics experts. Managed care professionals. Key clinical specialists. This is where the worlds of clinical, regulatory, and economical outcomes for specialized pharmaceutical biotechnology meet: The Center for Biosimilars is your online resource for emerging technologies, with a focus on improving critical thinking in the field to impact patient outcomes. We’ll discuss the current landscape for advanced health care management—reviewing emerging treatment paradigms, approaches, and considerations—all by authoritative industry voices.

Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747
Copyright © 2006-2019 Intellisphere, LLC. All Rights Reserved.